These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38094526)

  • 41. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
    Burton HE; Mitchell SA; Watt M
    Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
    Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Initial vancomycin versus metronidazole for the treatment of first-episode non-severe
    Zhang K; Beckett P; Abouanaser S; Smieja M
    Antimicrob Steward Healthc Epidemiol; 2021; 1(1):e27. PubMed ID: 36168487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A retrospective budget impact analysis of fidaxomicin treatment for
    Siefen AC; Kurte MS; Bauer AM; Cornely OA; Wingen-Heimann S; Kron F
    Expert Rev Pharmacoecon Outcomes Res; 2024 Oct; 24(8):933-942. PubMed ID: 38712561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
    Okumura H; Fukushima A; Taieb V; Shoji S; English M
    J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibiotic Therapies for Clostridioides difficile Infection in Children.
    Gonzales-Luna AJ; Carlson TJ; Garey KW
    J Pediatric Infect Dis Soc; 2021 Nov; 10(Supplement_3):S52-S57. PubMed ID: 34791393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
    Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
    Petrella LA; Sambol SP; Cheknis A; Nagaro K; Kean Y; Sears PS; Babakhani F; Johnson S; Gerding DN
    Clin Infect Dis; 2012 Aug; 55(3):351-7. PubMed ID: 22523271
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
    Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
    Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conventional versus extended-pulsed fidaxomicin dosing in patients at high risk of recurrence of Clostridioides difficile infection: a propensity score analysis.
    Escudero-Sánchez R; Rubio Martín E; Vizcarra P; Braojos Sánchez F; Diaz Gago Á; Del Campo Albendea L; Muriel A; Halperin A; Ponce Alonso M; Moreno Guillén S; Cobo J
    J Antimicrob Chemother; 2023 Mar; 78(3):823-827. PubMed ID: 36861316
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
    Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
    J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fidaxomicin for the treatment of
    Skinner AM; Scardina T; Kociolek LK
    Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of Clostridioides difficile Infection, A Single-Center Real-World Experience.
    Alsoubani M; Chow JK; Rodday AM; McDermott LA; Walk ST; Kent DM; Snydman DR
    J Infect Dis; 2024 Dec; 230(6):1501-1509. PubMed ID: 38779889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study.
    Gentry CA; Nguyen PK; Thind S; Kurdgelashvili G; Skrepnek GH; Williams RJ
    Clin Microbiol Infect; 2019 Aug; 25(8):987-993. PubMed ID: 30583055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.
    Rubio-Terrés C; Aguado JM; Almirante B; Cobo J; Grau S; Salavert M; González Antona Sánchez E; López Gutiérrez C; Rubio-Rodríguez D
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1105-1111. PubMed ID: 30989419
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating
    Mori N; Hirai J; Ohashi W; Asai N; Shibata Y; Mikamo H
    Antibiotics (Basel); 2023 Aug; 12(8):. PubMed ID: 37627743
    [No Abstract]   [Full Text] [Related]  

  • 60. Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis.
    Dai J; Gong J; Guo R
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1727-1737. PubMed ID: 36057672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.